JP2021522266A5 - - Google Patents
Info
- Publication number
- JP2021522266A5 JP2021522266A5 JP2020560247A JP2020560247A JP2021522266A5 JP 2021522266 A5 JP2021522266 A5 JP 2021522266A5 JP 2020560247 A JP2020560247 A JP 2020560247A JP 2020560247 A JP2020560247 A JP 2020560247A JP 2021522266 A5 JP2021522266 A5 JP 2021522266A5
- Authority
- JP
- Japan
- Prior art keywords
- abcb5
- pip2
- composition
- cancer
- isoform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024061950A JP2024154382A (ja) | 2018-04-25 | 2024-04-08 | Ａｂｃｂ５のリガンドおよび基質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662670P | 2018-04-25 | 2018-04-25 | |
| US62/662,670 | 2018-04-25 | ||
| PCT/US2019/029235 WO2019210109A1 (en) | 2018-04-25 | 2019-04-25 | Abcb5 ligands and substrates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024061950A Division JP2024154382A (ja) | 2018-04-25 | 2024-04-08 | Ａｂｃｂ５のリガンドおよび基質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522266A JP2021522266A (ja) | 2021-08-30 |
| JP2021522266A5 true JP2021522266A5 (enExample) | 2022-05-09 |
| JP7611701B2 JP7611701B2 (ja) | 2025-01-10 |
Family
ID=68295729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560247A Active JP7611701B2 (ja) | 2018-04-25 | 2019-04-25 | Ａｂｃｂ５のリガンドおよび基質 |
| JP2024061950A Pending JP2024154382A (ja) | 2018-04-25 | 2024-04-08 | Ａｂｃｂ５のリガンドおよび基質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024061950A Pending JP2024154382A (ja) | 2018-04-25 | 2024-04-08 | Ａｂｃｂ５のリガンドおよび基質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12448461B2 (enExample) |
| EP (1) | EP3784249A4 (enExample) |
| JP (2) | JP7611701B2 (enExample) |
| KR (2) | KR20260025888A (enExample) |
| CN (1) | CN112423765B (enExample) |
| AU (2) | AU2019257728A1 (enExample) |
| CA (1) | CA3097875A1 (enExample) |
| MX (1) | MX2020011297A (enExample) |
| SG (1) | SG11202010260XA (enExample) |
| WO (1) | WO2019210109A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2685492C (en) | 2006-05-31 | 2018-01-16 | The Brigham And Women's Hospital, Inc. | Abcb5 positive mesenchymal stem cells as immunomodulators |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| BR112015028193B8 (pt) | 2013-05-10 | 2023-04-18 | Childrens Medical Center | Suporte para cicatrização de feridas |
| CN111007240A (zh) * | 2019-12-02 | 2020-04-14 | 中国医学科学院北京协和医院 | 一种基于crispr技术的均相酶免疫检验系统及其方法和应用 |
| CA3180226A1 (en) * | 2020-04-15 | 2021-10-21 | Children's Medical Center Corporation | Targeting abcb5 in glioblastoma multiforme |
| CN113082210B (zh) * | 2021-03-09 | 2023-04-18 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种肿瘤化疗药物组合物 |
| CN116445573A (zh) * | 2022-08-30 | 2023-07-18 | 苏州大学 | 一种以抑制trim54泛素化降解stat2为靶点的抗病毒ade药物筛选方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587465T2 (de) | 1984-09-10 | 1994-01-20 | Hsc Res Dev Corp | Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS. |
| US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
| DE69739540D1 (de) | 1996-04-19 | 2009-10-01 | Osiris Therapeutics Inc | Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen |
| US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
| DE69922933T2 (de) | 1998-03-13 | 2005-12-29 | Osiris Therapeutics, Inc. | Anwendungen für humane nicht autologe, mesenchymale stammzellen |
| US6368636B1 (en) | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| CA2266805C (en) | 1998-03-27 | 2015-04-28 | An-Go-Gen Inc. | Cell-based gene therapy in the treatment of pulmonary disorders |
| JP2002510655A (ja) | 1998-04-03 | 2002-04-09 | オシリス セラピューティクス，インコーポレイテッド | 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用 |
| WO1999061587A1 (en) | 1998-05-29 | 1999-12-02 | Osiris Therapeutics, Inc. | Human cd45+ and/or fibroblast + mesenchymal stem cells |
| AU785363B2 (en) | 1999-09-28 | 2007-02-01 | Gentest Corporation | P-glycoproteins and uses thereof |
| US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
| CA2411101C (en) | 2000-06-05 | 2018-01-16 | Brigham And Women's Hospital, Inc. | A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
| US20040175366A1 (en) | 2003-03-07 | 2004-09-09 | Acell, Inc. | Scaffold for cell growth and differentiation |
| US7829336B2 (en) | 2003-11-24 | 2010-11-09 | The Rockefeller University | Method for isolating a self-renewing, multipotent, slow-cycling cell |
| US20050186672A1 (en) | 2004-01-27 | 2005-08-25 | Reliance Life Sciences Pvt. Ltd. | Tissue system with undifferentiated stem cells derived from corneal limbus |
| WO2006103685A2 (en) | 2005-03-28 | 2006-10-05 | Vision Research Foundation | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue |
| US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
| WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
| CA2685492C (en) | 2006-05-31 | 2018-01-16 | The Brigham And Women's Hospital, Inc. | Abcb5 positive mesenchymal stem cells as immunomodulators |
| GB0610778D0 (en) * | 2006-05-31 | 2006-07-12 | Het Nl Kanker I | Phosphatidylinositol phospahte and apoptosis |
| EP2052089A4 (en) | 2006-07-28 | 2010-05-05 | Chundsell Medicals Ab | EMBRYONIC STEM CELL MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| PL2155248T3 (pl) | 2007-04-12 | 2015-12-31 | Brigham & Womens Hospital Inc | Celowanie w ABCB5 w terapii nowotworowej |
| US9011840B2 (en) | 2008-03-14 | 2015-04-21 | The Board Of Trustees Of The University Of Illinois | Activated mesenchymal stem cells for wound healing and impaired tissue regeneration |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| ES2796111T3 (es) | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| WO2010065711A1 (en) * | 2008-12-04 | 2010-06-10 | Adimab, Inc. | An abcb5 epitope and antibodies thereto for the treatment of cancer |
| KR101138091B1 (ko) | 2011-08-31 | 2012-04-24 | 세원셀론텍(주) | 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 |
| ES2860573T3 (es) | 2013-02-19 | 2021-10-05 | Childrens Medical Center | Células madre ABCB5(+) para el tratamiento de enfermedades oculares |
| BR112015028193B8 (pt) * | 2013-05-10 | 2023-04-18 | Childrens Medical Center | Suporte para cicatrização de feridas |
| US20180134771A1 (en) * | 2015-05-07 | 2018-05-17 | Bioxcel Corporation | Novel immunomodulatory therapeutic strategies targeting tumors in cancer |
| WO2016184793A1 (en) * | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma |
| EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
| WO2018185584A1 (en) | 2017-04-05 | 2018-10-11 | Pluristem Ltd. | Methods and compositions for treating acute lung injury and respiratory distress syndrome |
| JP7849972B2 (ja) | 2019-03-28 | 2026-04-22 | ザ チルドレンズ メディカル センター コーポレーション | 高機能な製造されたａｂｃｂ５＋間葉系幹細胞 |
| JP7714535B2 (ja) | 2019-10-18 | 2025-07-29 | アムニオティクス・アーベー | 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置 |
| US20230148432A1 (en) | 2020-03-30 | 2023-05-11 | Children's Medical Center Corporation | Use of stem cells for treatment of excessive inflammation |
| CA3180226A1 (en) | 2020-04-15 | 2021-10-21 | Children's Medical Center Corporation | Targeting abcb5 in glioblastoma multiforme |
| JP2023524102A (ja) | 2020-04-30 | 2023-06-08 | ザ チルドレンズ メディカル センター コーポレーション | Ａｂｃｂ５に特異的な抗体およびその使用 |
-
2019
- 2019-04-25 CA CA3097875A patent/CA3097875A1/en active Pending
- 2019-04-25 EP EP19793673.5A patent/EP3784249A4/en active Pending
- 2019-04-25 KR KR1020267004454A patent/KR20260025888A/ko active Pending
- 2019-04-25 JP JP2020560247A patent/JP7611701B2/ja active Active
- 2019-04-25 KR KR1020207033473A patent/KR102928177B1/ko active Active
- 2019-04-25 US US17/050,424 patent/US12448461B2/en active Active
- 2019-04-25 AU AU2019257728A patent/AU2019257728A1/en not_active Abandoned
- 2019-04-25 WO PCT/US2019/029235 patent/WO2019210109A1/en not_active Ceased
- 2019-04-25 SG SG11202010260XA patent/SG11202010260XA/en unknown
- 2019-04-25 CN CN201980027801.8A patent/CN112423765B/zh active Active
- 2019-04-25 MX MX2020011297A patent/MX2020011297A/es unknown
-
2024
- 2024-04-08 JP JP2024061950A patent/JP2024154382A/ja active Pending
-
2025
- 2025-03-13 AU AU2025201810A patent/AU2025201810A1/en active Pending
- 2025-09-25 US US19/340,094 patent/US20260184810A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Deregulation of FoxM1b leads to tumour metastasis | |
| Yamanishi et al. | Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis | |
| Hou et al. | Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways | |
| Kolachala et al. | Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation | |
| Wang et al. | Interleukin-6 induces keratin expression in intestinal epithelial cells: potential role of keratin-8 in interleukin-6-induced barrier function alterations | |
| JP2022521454A (ja) | 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法 | |
| KR101436578B1 (ko) | 척추 측만증의 발병 위험성을 측정하는 방법, 척추 측만증에 걸린 대상자를 계층화하는 방법, 척추 측만증에 걸린 대상자에 있어서 고정기의 효능을 평가하는 방법, 및 이를 위한 키트 | |
| EP3823443A1 (en) | Non-human animal models of ditra disease and uses thereof | |
| Cuttitta et al. | Adrenomedullin functions as an important tumor survival factor in human carcinogenesis | |
| Azizan et al. | RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer | |
| US9254309B2 (en) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation | |
| Collins-Hooper et al. | Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice | |
| Kim et al. | Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist | |
| US20130158087A1 (en) | Tg2 inhibitors and uses thereof | |
| JP2005537245A5 (ja) | プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法 | |
| KR20220025713A (ko) | 유전성 신경병증 및 연관 장애의 치료 및 검출 | |
| JP6262707B2 (ja) | がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物 | |
| Ruhr et al. | The differential role of renoguanylin in osmoregulation and apical Cl−/HCO3− exchange activity in the posterior intestine of the Gulf toadfish (Opsanus beta) | |
| WO2020219926A1 (en) | Treatment of cancer with cdk inhibitors | |
| Gordon et al. | MED220/thyroid receptor-associated protein 220 functions as a transcriptional coactivator with Pit-1 and GATA-2 on the thyrotropin-β promoter in thyrotropes | |
| WO2016176617A2 (en) | Method for treating high-grade gliomas | |
| Carlson et al. | fMLP induces Hsp27 expression, attenuates NF-κB activation, and confers intestinal epithelial cell protection | |
| Tada et al. | The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma | |
| US11419894B2 (en) | Modified natural killer cells for the treatment of cancer | |
| Tajima et al. | Enhanced vascular contraction induced by exposure to angiotensin II mediated by endothelin-1 biosynthesis following PKCβ activation |